Safety of Gam-COVID-Vac (Sputnik V) Combined Vector Vaccine in Patients With Immunoinflammatory Rheumatic Diseases: Preliminary Data
Antibiotiki i Khimioterapiya
; 67(45145):33-39, 2022.
Artículo
en Ruso
| EMBASE | ID: covidwho-2242363
ABSTRACT
Background. Patients with autoimmune and inflammatory rheumatic diseases (AIRDs) are at high risk of developing COVID-19. Vaccination is an effective method of preventing this disease, which may be unsafe for patients with AIRDs. The aim of the study is to assess the safety of Gam-COVID-Vac in patients with IVRD in real clinical practice. Material and methods. A cross-sectional study was carried out. The main group consisted of patients with AIRDs, the control group consisted of individuals without AIRDs. All participants were interviewed by the research physician using a unified questionnaire, additional information was obtained from medical records. Results. The study included 222 patients with AIRDs (119 with rheumatoid arthritis, 36 with ankylosing spondylitis, 17 with psoriatic arthritis, 17 with Sjögren's disease, 10 with undifferentiated spondyloarthritis, 8 with systemic lupus erythematosus, 4 with metabolic arthritis, 3 with systemic scleroderma, 3 with systemic vasculitis, 2 with polymyalgia rheumatica, 2 with undifferentiated systemic connective tissue disease, 1 with adult Still's disease) and 111 patients without AIRDs. The number of patients with AIRDs who had a combination of local and systemic adverse events (AE) on the introduction of the first component of the vaccine was significantly less than in the control group (22.1 and 44.1%, respectively, P<0.001). Similar differences were also noted after the introduction of the second component (14.0 and 29.7%, respectively, P<0.001). AEs such as pain at the injection site without restriction of movement, weakness, fever, arthralgia/myalgia, headache, and chills were significantly more common in the control group after the introduction of the first component of the vaccine. After complete immunization, AEs were absent in 35.6% of patients with AIRDs and in 21.6% of control group patients (P=0.01). Exacerbations of AIRDs and new autoimmune phenomena were not registered in any cases. Conclusions. According to preliminary data, immunization of patients with AIRDs with the Gam-COVID-Vac combined vector vaccine appears to be quite safe.
adult; adult onset Still disease; ankylosing spondylitis; arthralgia; article; chill; clinical practice; connective tissue disease; controlled study; coronavirus disease 2019; cross-sectional study; disease exacerbation; drug combination; drug safety; female; fever; headache; human; immunization; injection site pain; major clinical study; male; medical record; physician; preliminary data; psoriatic arthritis; questionnaire; rheumatic disease; rheumatic polymyalgia; rheumatoid arthritis; spondylarthritis; systemic lupus erythematosus; systemic sclerosis; systemic vasculitis; vaccination; weakness; sputnik v vaccine
Texto completo:
Disponible
Colección:
Bases de datos de organismos internacionales
Base de datos:
EMBASE
Tópicos:
Vacunas
Idioma:
Ruso
Revista:
Antibiotiki i Khimioterapiya
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS